JRSIS HEALTH CARE Corp Liquidation Value

JRSS Hospitals

Cash & Equivalents

$1,372
As of 2024-09-30
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $1,372
Total Obligations: -$2.31M
$-2.31M
Per share: $-0.03
Period: 2024-09-30
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $1,372
AR: $575,205
Total Obligations: -$2.31M
$-1.73M
Per share: $-0.02
Period: 2024-09-30
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $1,372
AR: $575,205
Inventory: $361,774
Total Obligations: -$2.31M
$-1.37M
Per share: $-0.02
Period: 2024-09-30
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-2.31M$-0.03
Liquid Liquidation Value$-1.73M$-0.02
Operating Liquidation Value$-1.37M$-0.02

Key Components (as of 2024-09-30)

Data as of 2024-09-30 from 10-Q filed 2024-12-20. View on SEC EDGAR →

Cash & Equivalents$1,372
Accounts Receivable$575,205
Inventory$361,774
Current Liabilities$2.30M
Long-term Debt (?)$6,311
Op. Lease Liability (?)N/A
Finance Lease (?)N/A
Shares Outstanding84.6M

Explore all 137 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2024-09-30$1,372$575,205$361,774N/A$2.30M$6,311N/AN/A
2024-06-30$445,902$555,837$397,825N/A$2.11M$12,188$0N/A
2024-03-31$323,611$603,022$445,500N/A$2.40M$18,401$0N/A
2023-12-31$118,114$714,658$455,240N/A$2.28M$24,950$0N/A
2023-09-30$33,387$2,836$-24,206$8,000$90,969N/A$6,705N/A
2023-06-30$28,220$13,791$-23,692$8,000$69,393N/A$10,730N/A
2023-03-31$18,777$2,999N/A$20,000$36,968N/A$15,487N/A
2022-12-31$58,616$683,452$562,015$24,711$43,231$49,709$2,235$1,430

Comments

SEC Filings

PeriodFormFiledLink
2024-09-30 10-Q 2024-12-20 View
2024-06-30 10-Q 2024-09-05 View
2024-03-31 10-Q 2024-05-29 View
2023-12-31 10-K 2024-04-26 View
2023-09-30 10-Q 2023-11-15 View
2023-06-30 10-Q 2023-08-21 View
2023-03-31 10-Q 2023-05-22 View
2022-12-31 10-K/A 2023-08-31 View

AI Insights

AI Insight·Generated 2026-05-06

JRSIS Health Care Corp (JRSS) is a micro-cap China-based smart medical equipment and services company operating through a VIE structure (Yongzhou JIT, 85.53% controlled). The September 30, 2024 balance sheet shows total assets of $2.07M against total liabilities of $2.31M, producing consolidated stockholders' equity of negative $234K. Under the liquidation lens, the recovery posture is deeply negative. MFFAIS reports a cash liquidation value of negative $2.31M, liquid liquidation value of negative $1.73M, and operating liquidation value of negative $1.37M, all consistent with a face-value liability stack that overwhelms even optimistically haircut assets. Key drivers: (1) Cash is $1,372 — effectively zero. (2) Accounts receivable of $575K is concentrated 91% in a single customer (Customer A) for Q3 2024; at 90-95% recovery that yields ~$517-546K but collectability risk is elevated given single-counterparty concentration. (3) Inventory of $362K net (gross $410K less $48K reserve) applies at ~60% recovery = ~$217K. (4) PP&E net $43K yields at most $30K at 50-70% haircut. (5) Intangibles net $241K — zero liquidation value. Total haircut asset pool approximates $800-900K against $2.31M in face-value liabilities, confirming negative equity recovery of roughly $1.4-1.5M — consistent with the MFFAIS OLV figure. Since the prior filing (June 30, 2024 10-Q), short-term borrowings grew from approximately $983K to $1.31M (33% QoQ increase) driven by new draws from Bank of China and China Construction Bank. Accounts receivable from related parties surged $578K YTD per the cash flow statement, indicating a large portion of reported AR is intercompany or related-party with uncertain enforceability in liquidation. The working capital deficit widened to $512K at September 30, 2024 versus $404K at September 30, 2023. Management has disclosed substantial doubt about going concern. Operating cash outflow for the nine months was $826K versus $421K inflow for the same period in 2023 — a significant reversal. The filing discusses a $138K inventory impairment reversal in the nine-month cash flow but does not separately XBRL-tag the reversal breakdown; only the net InventoryWriteDown tag of negative $138K appears in the XBRL, indicating a reversal rather than a charge. The accumulated deficit stands at $3.88M. The VIE structure introduces an additional liquidation risk: contractual arrangements rather than direct equity ownership govern control of YZ JIT, and the NCI balance is itself negative at $37K, meaning the minority interest provides no buffer. RMB-denominated assets subject to currency remittance restrictions further compress repatriation-adjusted recovery.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...